Please assess the completion status of the following clinical trial:

Trial Title: Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Localized adenocarcinoma of the prostate with a Gleason score of 3+3 (group I patients) or 3+4 (group II patients)~* Percentage of tumor biopsy invasion \<50% and/or with a size of maximum 8 mm~* With a number of positive tumor biopsies ≤3 (group I patients) or ≤ 5 (group II patients)~* TNM stage T1-2a N0 M0 (group I patients); TNM stage T1-2c N0 M0 (group II patients)~* PSA level at diagnosis \< 10 ng/ml for group I patients; \< 15 ng/ml for group II patients~* Tumor volume negative (group I patients); positive (group II patients)~* Absence of extra-capsular extension~* Life expectancy \> 10 years~* Signed informed consent~* Patient has elected active surveillance as preferred management plan for the prostate cancer~Exclusion Criteria:~* Previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery or chemotherapy)~* Patients with hypogonadism

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Epstein + (group I) (Type: ACTIVE_COMPARATOR): Epstein + (Group I) PSA \<10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;~% of tumor biopsy invasion \<50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0
- Epstein - (group II) (Type: EXPERIMENTAL): Epstein - (Group II) PSA \<15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12~% of tumor biopsy invasion \<50% and ≤8mm; mp MRI positive; T1-T2c N0 M0

Based on this trial design, predict the completion outcome and termination type (if applicable).